SEC Contract Filing

Filing Date: 2017-03-15

Document Content:
<DOCUMENT>
<TYPE>EX-10.5(B)
<SEQUENCE>5
<FILENAME>aimt-ex105b_1498.htm
<DESCRIPTION>EX-10.5(B)
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
aimt-ex105b_1498.htm
</title>
</head>
<!-- NG Converter v4.0.6.4 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.5(b)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AIMMUNE THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES PURCHASE AGREEMENT</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Securities Purchase Agreement (&#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is made as of November 3, 2016 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), between Aimmune Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Nestle Health Science US Holdings, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Purchaser</font>&#8221;). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AGREEMENT</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Purchaser hereby agree as follows:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Section 1.&nbsp;&nbsp;AUTHORIZATION OF SALE OF SECURITIES.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has authorized the sale and issuance to the Purchaser of 7,552,084 shares of its Common Stock, par value $0.0001 per share (the &#8220;<font style="text-decoration:underline;">Common Stock</font>&#8221;), on the terms and subject to the conditions set forth in this Agreement.&nbsp;&nbsp;The shares of Common Stock sold hereunder at the Closing (as defined below) shall be referred to as the &#8220;<font style="text-decoration:underline;">Shares</font>.&#8221;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 2.&nbsp;&nbsp;AGREEMENT TO SELL AND PURCHASE THE SHARES.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:6.94%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc400771532"></a><a name="_Toc400771596"></a><a name="_Toc400772101"></a><a name="_Toc400772639"></a><a name="_Toc412036896"></a>At the Closing (as defined in Section 3), the Company will sell to Purchaser, and Purchaser will purchase from the Company the Shares at a purchase price of $19.20 per Share for an aggregate purchase price of $145,000,012.80 (the &#8220;<font style="text-decoration:underline;">Aggregate Purchase Price</font>&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 3.&nbsp;&nbsp;CLOSING AND DELIVERY.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc400771535"></a><a name="_Toc400771599"></a><a name="_Toc400772104"></a><a name="_Toc400772645"></a><a name="_Toc412036902"></a>3.1<font style="font-weight:bold;margin-left:36pt;"></font><font style="font-weight:bold;">Closing.</font>&nbsp;&nbsp;Subject to the terms and conditions set forth herein, the closing of the purchase and sale of the Shares pursuant to this Agreement (the &#8220;<font style="text-decoration:underline;">Closing</font>&#8221;) shall be held on the date (the &#8220;<font style="text-decoration:underline;">Closing Date</font>&#8221;) that is three (3) business days following the satisfaction of the conditions precedent set out in <font style="text-decoration:underline;">Sections 6</font> and <font style="text-decoration:underline;">7</font> hereof at the offices of Latham &amp; Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, or on such other date and place as may be agreed to by the Company and the Purchaser.&nbsp;&nbsp;At the Closing, the Purchaser shall pay the Aggregate Purchase Price to the Company in accordance with Section 6.1, and each of the Purchaser and the Company shall execute and deliver to the other, each of the agreements or other documents required to be executed by it as of the Closing Date pursuant to this <font st